Australia’s agreement to spend about 1 billion Australian dollars (U.S.$766 million) over 5 years in exchange for an unlimited volume of hepatitis C drugs suggests that, under certain conditions, innovative approaches to payment can remove price as a barrier to access.
No takes yet. Share an insight, caveat, or question.
Moon et al. (2019) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: